Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619987 | 0.86 | ATM (0.64) | ATMSIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL11114131 | 0.86 | ATM (0.64) | ATMSIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL1115177 | 0.85 | KDM4E (0.63) | ATMSIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL10258595 | 0.83 | ATM (0.57) | ATMSIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL655154 | 0.82 | ATM (0.59) | ATMSIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL31329843 | 0.82 | ATM (0.59) | ATMSIGMAR1ADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL1238351 | 0.81 | ATM (0.58) | ATMSIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL742078 | 0.80 | SIGMAR1 (0.65) | ATMSIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL16503899 | 0.80 | SIGMAR1 (0.65) | ATMSIGMAR1ADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL12480829 | 0.80 | ATM (0.57) | ATMSIGMAR1ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371410-A | Chromone spiro compound and preparation method and application thereof | 中国药科大学 | 2025-01-28 | — | — | CN | disclosed |
| US-8598220-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-8071611-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071611-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-8022060-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-8022060-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2011-09-08 | — | — | US | disclosed |
| US-7598261-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598261-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090233953-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | US | disclosed |
| EP-2012778-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | Abbott Laboratories (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | ADOLOR CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | ADOLOR CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070249614-A1 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007121299-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233953-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | OPRL1, AVPR1A, TRPV1 | ATM 4479/4885SIGMAR1 163/4885ADRA1D 22/4885 |
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | ATM 4539/4885SIGMAR1 27/4885ADRA1D 39/4885 |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | OPRK1, OPRD1, OPRL1 | ATM 4539/4885SIGMAR1 27/4885ADRA1D 39/4885 |
| US-20070249614-A1 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof | OPRL1, AVPR1A, AVPR1B | ATM 4428/4885SIGMAR1 181/4885ADRA1D 21/4885 |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | ATM 4539/4885SIGMAR1 27/4885ADRA1D 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.